Irinotecan chemotherapy during valproic acid treatment: Pharmacokinetic interaction and hepatotoxicity

Jong, Floris A. de; Bol, Jessica M. van der; Mathijssen, Ron H.J.; Loos, Walter J.; Mathôt, Ron A. A.; Kitzen, Jos; Bent, Martin J. van den; Verweij, Jaap

doi:10.4161/cbt.6.9.4567

Cited by 22 publications

(8 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…79 In contrast, the exposure to SN-38 was reduced in a patient who was co-medicated with valproate and irinotecan. 80 These findings are anecdotal yet support the recommendation to avoid sacituzumab govitecanvalproate combinations (Figure 3).…”

Section: Potential Antiseizure Medication Effects the Pharmacokinetics Of Mabsmentioning

confidence: 56%

Not your usual drug‐drug interactions: Monoclonal antibody–based therapeutics may interact with antiseizure medications

et al. 2021

View full text Add to dashboard Cite

Therapeutic monoclonal antibodies (mAbs) have emerged as the fastest growing drug class. As such, mAbs are increasingly being co-prescribed with other drugs, including antiseizure medications (ASMs). Although mAbs do not share direct targets or mechanisms of disposition with small-molecule drugs (SMDs), combining therapeutics of both types can increase the risk of adverse effects and treatment failure. The primary goal of this literature review was identifying mAb-ASM combinations requiring the attention of professionals who are treating patients with epilepsy. Systematic PubMed and Embase searches were performed for terms relating to mAbs, ASMs, drug interactions, and their combinations. Additional information was obtained from documents from the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

show abstract

Section: Potential Antiseizure Medication Effects the Pharmacokinetics Of Mabsmentioning

confidence: 56%

Not your usual drug‐drug interactions: Monoclonal antibody–based therapeutics may interact with antiseizure medications

et al. 2021

View full text Add to dashboard Cite

show abstract

“…For example, co-administration of valproic acid can increase incidence of liver injury by changing the disposition of irinotecan. 20 Therefore, liver function of FOLFIRI recipients should be monitored and co-administration of hepatotoxic medications should be avoided. Patient case 2 was liver injury induced by S-1 plus paclitaxel.…”

Section: Discussionmentioning

confidence: 99%

A simple method to identify undiagnosed drug-induced liver injury (DILI) and its application in oncology pharmacy practice

Wen

et al. 2019

J Oncol Pharm Pract

View full text Add to dashboard Cite

Aims To establish a simple method to identify chemotherapy-induced liver injury among oncological patients. To evaluate current clinical approach to elevated laboratory liver test results. Methods A total of 289 patients admitted to oncology department who had systemic chemotherapy episodes for cancer treatment from 1 January 2017 to 31 December 2017 were identified. With aid of healthcare information system, Hy's law was applied to laboratory liver test results to identify potential hepatocellular drug-induced liver injury cases. Medical record review was carried out among identified patients to exclude liver dysfunction of alternative causes. Current clinical approach to elevated laboratory liver tests was evaluated through medical record review. Results Of 289 patients who were treated by systemic chemotherapies, there were 123 patients with elevated laboratory liver tests, among which 8 patients were suspected as potential Hy's law cases. After medical record review, there were two patients determined with chemotherapy-associated liver injury, caused by 5-fluorouracil, leucovorin, irinotecan, and S-1 plus paclitaxel separately. Of eight potential Hy's law cases, seven (87.5%) patients were prescribed with ≥2 kinds of liver protectants and remained treated with traditional Chinese medicine for decoction. Conclusions A reliable and simple method to identify undiagnosed drug-induced liver injury was successfully established. An annual incidence of 0.69% of chemotherapy-associated liver injury in oncology department of the setting was found.

show abstract

“…26,27 Concomitant smoking also resulted in reduced plasma-concentrations of irinotecan and SN-38. 28 Reduced levels of SN-38 were seen when irinotecan was combined with valproic acid, 29 and with St. John's wort. 30 Higher levels of SN-38 were seen in combination with lopinavir/ritonavir and the combined CYP3A and UGT1A inhibitor ketoconazole, 17,31,32 and when irinotecan was combined with tacrolimus.…”

Section: Discussionmentioning

confidence: 99%

Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: A prospective cross-over drug–drug interaction study

Bol

Loos

Jong

et al. 2011

European Journal of Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

Irinotecan chemotherapy during valproic acid treatment: Pharmacokinetic interaction and hepatotoxicity

Cited by 22 publications

References 37 publications

Not your usual drug‐drug interactions: Monoclonal antibody–based therapeutics may interact with antiseizure medications

Not your usual drug‐drug interactions: Monoclonal antibody–based therapeutics may interact with antiseizure medications

A simple method to identify undiagnosed drug-induced liver injury (DILI) and its application in oncology pharmacy practice

Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: A prospective cross-over drug–drug interaction study

Contact Info

Product

Resources

About